Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2013.
The cash balance at 30 September 2013 was $31.5 million, a net cash burn of $2.3 million for the quarter.
Starpharma's Dendrimer-Docetaxel eliminates neutropenia
Starpharma today announced additional positive results for its dendrimer formulation of the major chemotherapeutic, docetaxel (Taxotere®), ahead of its advancement into clinical trials later this year.
The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley
ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.
Sky Business News: Interview with Starpharma CEO Jackie Fairley
Starpharma CEO Dr Jackie Fairley joined Sky News to discuss the positive results of the Company’s pre-clinical trial of Dendrimer-Enhanced Oxaliplatin. Starpharma’s dendrimer version of the blockbuster colon and colorectal cancer drug was shown to be less neurotoxic than conventional oxaliplatin.
Reduced neurotoxicity with SPL's dendrimer enhanced oxaliplatin
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced further positive results for its Dendrimer-Enhanced Oxaliplatin (DEO), specifically that its dendrimer version of oxaliplatin results in a significant reduction in the serious neurotoxicity commonly seen with oxaliplatin.
Starpharma signs Priostar Agrochemical Partnership with Gowan
Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) and Gowan Company LLC today announced a new partnership using Starpharma’s Priostar® dendrimer technology in crop protection formulations.
Under the agreement, Starpharma’s Priostar® dendrimers will be evaluated as potential enhancements for certain Gowan products intended for high value markets.
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Melbourne, Australia: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved improved tumour-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, oxaliplatin (ELOXATIN®).
These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin compared with ELOXATIN® (oxaliplatin) in a colon cancer model (xenograft).
Eureka Report: Uncapped biotechs step up
Small caps reporter Brendon Lau, reported on Starpharma’s strong share price after the company announced improved efficacy and safety profile in its dendrimer-enhanced version of widely-used cancer drug oxaliplatin.
|
The Australian: Starpharma to develop improved cancer drug
The Australian online reported on Starpharma’s pre-clinical study of the effects of its dendrimer-enhanced oxaliplatin on colon cancer.
|
Herald Sun: Starpharma may be on to a good thing
Herald Sun business journalist John Beveridge reported on the versatility of Starpharma’s dendrimer technology.
"There is no secret why Starpharma is going after docetaxel given its sales of $US2.14 billion in 2009, but there is a long list of other potential drugs that could benefit from improved delivery mechanisms. The other thing I like about Starpharma is that it has lots of irons in the fire. Its phase-three Vivagel trials for relieving symptoms of bacterial vaginosis have potential to recover ground lost when trials as a cure for that disease marginally failed to reach their endpoint. Plus the potential for removing solvents and greatly improving the efficacy of a broad range of agricultural chemicals is a much-underestimated source of future profits for Starpharma."